Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen
✍ Scribed by Juan Morote; José Antonio Lorente; Gloria Encabo
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 414 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND. Biochemical markers of bone disease have been of interest as part of the investigation of prostate carcinoma and the monitoring of skeletal involvement. Bone isoenzyme of the alkaline phosphatase (BAP) is an indicator of the metabolism of the osteoblasts. An immunoradioanalyses with two monoclonal antibodies in sandwich was developed, allowing an accurate measurement of BAP concentration. The goal of the current study was to compare the clinical performance of BAP and prostate specific antigen (PSA) in patients with untreated prostate carcinoma and to determine whether or not BAP can provide valuable additional information to PSA regarding the degree of skeletal extension in patients with prostate carcinoma.